E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers B > Headlines for Basilea Pharmaceutica Ltd. > News item
Published on 5/17/2006 in the Prospect News Biotech Daily.

Basilea starts phase 3 pneumonia study

By Elaine Rigoli

Tampa, Fla., May 17 - Basilea Pharmaceutica Ltd. announced the start of a community-acquired pneumonia trial, further expanding the development program for ceftobiprole in collaboration with Johnson & Johnson Pharmaceutical Research and Development, LLC.

Basilea is an independent biopharmaceutical company with headquarters in Basel, Switzerland.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.